NO20080052L - G-Protein kopplede reseptoragonister - Google Patents
G-Protein kopplede reseptoragonisterInfo
- Publication number
- NO20080052L NO20080052L NO20080052A NO20080052A NO20080052L NO 20080052 L NO20080052 L NO 20080052L NO 20080052 A NO20080052 A NO 20080052A NO 20080052 A NO20080052 A NO 20080052A NO 20080052 L NO20080052 L NO 20080052L
- Authority
- NO
- Norway
- Prior art keywords
- receptor agonists
- coupled receptor
- protein coupled
- obesity
- diabetes
- Prior art date
Links
- 229940080349 GPR agonist Drugs 0.000 title 1
- 229940125633 GPCR agonist Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0513276A GB0513276D0 (en) | 2005-06-30 | 2005-06-30 | Compounds |
| GB0612897A GB0612897D0 (en) | 2006-06-29 | 2006-06-29 | GPCR agonists |
| PCT/GB2006/050182 WO2007003964A1 (fr) | 2005-06-30 | 2006-06-30 | Agonistes du récepteur couplé aux protéines g |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20080052L true NO20080052L (no) | 2008-01-23 |
Family
ID=37057179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20080052A NO20080052L (no) | 2005-06-30 | 2008-01-04 | G-Protein kopplede reseptoragonister |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090203676A1 (fr) |
| EP (1) | EP1909791A1 (fr) |
| JP (1) | JP2008545010A (fr) |
| KR (1) | KR20080025190A (fr) |
| AU (1) | AU2006264651A1 (fr) |
| BR (1) | BRPI0612599A2 (fr) |
| CA (1) | CA2613236A1 (fr) |
| MX (1) | MX2007016545A (fr) |
| NO (1) | NO20080052L (fr) |
| NZ (1) | NZ564758A (fr) |
| WO (1) | WO2007003964A1 (fr) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004009295T2 (de) | 2003-01-14 | 2008-07-03 | Arena Pharmaceuticals, Inc., San Diego | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| US20070197590A1 (en) * | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| BRPI0710839A2 (pt) * | 2006-04-06 | 2011-08-23 | Prosidion Ltd | agonistas heterocìclicos de gpcr |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| AU2007238805B2 (en) | 2006-04-11 | 2012-04-05 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| AU2007342531B2 (en) * | 2006-12-20 | 2011-10-13 | Merck Sharp & Dohme Corp. | Bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| JP2010514832A (ja) * | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンｇｐｃｒアゴニスト |
| SI2114933T1 (sl) | 2007-01-04 | 2012-01-31 | Prosidion Ltd Windrush Court | Piperidinski gpcr-agonisti |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
| EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
| EP2200609A1 (fr) | 2007-09-10 | 2010-06-30 | Prosidion Limited | Composés pour le traitement de troubles métaboliques |
| EP2197873B1 (fr) | 2007-09-20 | 2014-07-16 | Irm Llc | Composés et compositions en tant que modulateurs de l'activité de gpr119 |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| RU2010126842A (ru) | 2007-12-05 | 2012-01-10 | Астразенека Аб (Se) | Производные пиперазина и их применение в качестве модуляторов рецептора лептина |
| WO2009105722A1 (fr) * | 2008-02-22 | 2009-08-27 | Irm Llc | Composés et compositions comme modulateurs d'activité de gpr119 |
| CA2714703A1 (fr) * | 2008-02-22 | 2009-08-27 | Irm Llc | Composes et compositions comme modulateurs d'activite de gpr119 |
| EP2108960A1 (fr) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY |
| US8343990B2 (en) | 2008-04-14 | 2013-01-01 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
| EP2379542B1 (fr) | 2008-12-24 | 2013-02-13 | Cadila Healthcare Limited | Nouveaux dérivés d'oxime |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| EA201200046A1 (ru) | 2009-06-24 | 2012-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые соединения, фармацевтическая композиция и связанные с ними способы |
| JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
| WO2011002067A1 (fr) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | Composé hétérocyclique et son utilisation |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| BR112012008004A2 (pt) * | 2009-10-09 | 2016-03-29 | Irm Llc | compostos e composições como moduladores da atividade de gpr119 |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
| US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| EP2571864A1 (fr) | 2010-05-17 | 2013-03-27 | Array Biopharma, Inc. | Lactames à substitution pipéridinyle comme modulateurs de gpr119 |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US8785463B2 (en) | 2010-10-08 | 2014-07-22 | Cadila Healthcare Limited | GPR 119 agonists |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| WO2012066077A1 (fr) | 2010-11-18 | 2012-05-24 | Prosidion Limited | Dérivés 1,4 di substitués pyrolidine-3-yl-amine et leur utilisation pour le traitement de troubles métaboliques |
| WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (fr) | 2011-03-08 | 2014-12-17 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683705B1 (fr) | 2011-03-08 | 2015-04-22 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| AU2012240122B2 (en) | 2011-04-08 | 2016-08-25 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| WO2012145361A1 (fr) * | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
| WO2012170702A1 (fr) * | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
| EA031618B1 (ru) | 2011-06-09 | 2019-01-31 | Ризен Фармасьютикалз Са | Соединения-модуляторы gpr-119 |
| CA2838079A1 (fr) | 2011-06-16 | 2012-12-20 | Merck Sharp & Dohme Corp. | Composes cyclopropyles substitues, compositions contenant de tels composes et procedes de traitement |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| EP2760862B1 (fr) | 2011-09-27 | 2015-10-21 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| EP2760855B1 (fr) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Composés de cyclopropyle substitués, compositions contenant ces composés ainsi que leur utilisation pour le traitement du diabète de type 2 |
| EP2771000B1 (fr) | 2011-10-24 | 2016-05-04 | Merck Sharp & Dohme Corp. | Composés de pipéridinyle substitués utilisés comme agonistes du récepteur gpr119 |
| WO2013062837A1 (fr) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Dérivés de la pipéridine utilisés comme agonistes du récepteur gpr119 |
| WO2013066869A1 (fr) * | 2011-11-03 | 2013-05-10 | Array Biopharma Inc. | Lactames substitués par le pipéridinyle comme modulateurs de gpr119 |
| JP6101279B2 (ja) | 2011-11-15 | 2017-03-22 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｇｐｒ１１９アゴニストとして有用な置換シクロプロピル化合物 |
| US9452990B2 (en) | 2012-06-20 | 2016-09-27 | Novartis Ag | Complement pathway modulators and uses thereof |
| US10544117B2 (en) | 2014-09-10 | 2020-01-28 | Temple University—Of the Commonwealth System of Higher Education | 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| ES2995737T3 (en) | 2015-01-06 | 2025-02-11 | Arena Pharm Inc | Compound for use in treating conditions related to the s1p1 receptor |
| MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
| US10821106B2 (en) | 2015-08-21 | 2020-11-03 | Srx Cardio, Llc | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity |
| WO2017034990A1 (fr) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition et procédés d'utilisation de petites molécules de type tétrahydroisoquinoline pour se lier à pcsk9 et moduler l'activité protéique de pcsk9 |
| HK1257102A1 (zh) * | 2015-08-21 | 2019-10-11 | Portola Pharmaceuticals, Inc. | 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用 |
| US20190119236A1 (en) | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| WO2018151873A1 (fr) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| EP3801459B1 (fr) | 2018-06-06 | 2024-08-07 | Arena Pharmaceuticals, Inc. | Méthodes de traitement de troubles associés au récepteur s1p1 |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| EP4594294A1 (fr) * | 2022-09-30 | 2025-08-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Agonistes partiels du récepteur d3/d2 de la dopamine destinés au traitement de troubles neuropsychiatriques |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3332949A (en) * | 1962-11-13 | 1967-07-25 | Sterling Drug Inc | 1-phenyl-4-[2-(2-pyridyl)-ethyl] piperazines |
| US3133061A (en) * | 1962-11-13 | 1964-05-12 | Sterling Drug Inc | Piperidine carboxamides and derivatives thereof |
| FR2285883A1 (fr) * | 1974-09-30 | 1976-04-23 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes chimiques a activite bronchospasmolytique et antitussive, et procede pour leur obtention |
| US5229398A (en) * | 1990-02-27 | 1993-07-20 | Adir Et Compagnie | Aminomethylpiperidine compounds |
| GB9516709D0 (en) * | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| KR20000029984A (ko) * | 1996-08-14 | 2000-05-25 | 사라 엔 람베쓰 | 치환된피리미딘유도체및이의약학적용도 |
| AU5999798A (en) * | 1997-02-13 | 1998-09-08 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
| EP0966460A1 (fr) * | 1997-02-13 | 1999-12-29 | Zeneca Limited | Composes heterocycliques utilises comme inhibiteurs de l'oxydo-squalene cyclase |
| AU7976698A (en) * | 1997-06-18 | 1999-01-04 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| US6255302B1 (en) * | 1998-12-17 | 2001-07-03 | American Home Products Corporation | 1,4-piperazine derivatives |
| EP1301484A2 (fr) * | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Ligands du recepteur de la capsicine |
| HUP0401643A3 (en) * | 2001-07-26 | 2009-06-29 | Schering Corp | Substituted urea neuropeptide y y5 receptor antagonists, their use and pharmaceutical compositions containing them |
| ES2197003B1 (es) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| UY28538A1 (es) * | 2003-09-26 | 2005-04-29 | Vertex Pharma | Derivados de fenil-piperazina como moduladores de receptores muscarínicos |
| BRPI0516407A (pt) * | 2004-12-24 | 2008-09-02 | Prosidion Ltd | agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes |
| TWI385152B (zh) * | 2005-02-17 | 2013-02-11 | Astellas Pharma Inc | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (I) |
-
2006
- 2006-06-30 JP JP2008520009A patent/JP2008545010A/ja active Pending
- 2006-06-30 CA CA002613236A patent/CA2613236A1/fr not_active Abandoned
- 2006-06-30 NZ NZ564758A patent/NZ564758A/en not_active IP Right Cessation
- 2006-06-30 US US11/922,826 patent/US20090203676A1/en not_active Abandoned
- 2006-06-30 AU AU2006264651A patent/AU2006264651A1/en not_active Abandoned
- 2006-06-30 MX MX2007016545A patent/MX2007016545A/es unknown
- 2006-06-30 EP EP06744362A patent/EP1909791A1/fr not_active Withdrawn
- 2006-06-30 BR BRPI0612599-9A patent/BRPI0612599A2/pt not_active IP Right Cessation
- 2006-06-30 WO PCT/GB2006/050182 patent/WO2007003964A1/fr not_active Ceased
- 2006-06-30 KR KR1020087002531A patent/KR20080025190A/ko not_active Ceased
-
2008
- 2008-01-04 NO NO20080052A patent/NO20080052L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0612599A2 (pt) | 2010-11-23 |
| WO2007003964A1 (fr) | 2007-01-11 |
| CA2613236A1 (fr) | 2007-01-11 |
| MX2007016545A (es) | 2008-02-21 |
| KR20080025190A (ko) | 2008-03-19 |
| EP1909791A1 (fr) | 2008-04-16 |
| US20090203676A1 (en) | 2009-08-13 |
| JP2008545010A (ja) | 2008-12-11 |
| AU2006264651A1 (en) | 2007-01-11 |
| NZ564758A (en) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080052L (no) | G-Protein kopplede reseptoragonister | |
| NO20080010L (no) | GPCR-agonister | |
| EA015805B9 (ru) | Пиперидиновые агонисты gpcr | |
| NO20084364L (no) | Azetidin derivater som G-protein koblet reseptor (GPR119) agonister | |
| NO20084307L (no) | Heterocykliske GPCR agonister | |
| DK2114933T3 (da) | Piperidin-GPCR-agonister | |
| EA200900880A1 (ru) | Пиперидиновые агонисты gpcr | |
| WO2007003961A3 (fr) | Agonistes de gpcr | |
| EA200900878A1 (ru) | Пиперидиновые агонисты gpcr | |
| ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
| ATE557023T1 (de) | Piperidinylverbindungen als gpcr-agonisten | |
| BRPI0418149A (pt) | derivados heterocìclicos como agonistas do receptor de gprc | |
| NO20082445L (no) | Neuropeptid-2 reseptor-agonister | |
| MA32467B1 (fr) | Derives de piperidinyle agonistes de gpcr | |
| CL2008003847A1 (es) | Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad. | |
| NO20075082L (no) | Pyridin-3-karboksamidderivater som CB1-inversagonister | |
| NO20065260L (no) | Tri(cyklo)substituerte amidforbindelser | |
| ATE516300T1 (de) | Neuromedin-u-rezeptoragonisten und ihre verwendung | |
| WO2010036613A8 (fr) | Nouveaux dérivés de benzimidazole cycliques utiles en tant qu'agents anti-diabétiques | |
| BRPI0516407A (pt) | agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes | |
| NO20091734L (no) | Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse | |
| EP1797034A4 (fr) | Composes de sulfonyle comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1 | |
| NO20084403L (no) | Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I | |
| NO20074441L (no) | 1-benzylindol-2-karboksamidderivater | |
| CY1110753T1 (el) | Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |